Experts Say That Future Inhaled Anti-Viral Drug, Zanamivir Is Effective For Treatment And Prevention Of Influenza

September 28, 1998

28 September 1998: Experts have released new scientific information at a medical conference in the US which shows that an inhaled influenza drug, zanamivir, is effective for both treatment and prevention of the influenza infection.

"Zanamivir is a new antiviral that stops influenza dead in its tracks," said Professor Chris Silagy, Flinders Medical Centre, South Australia. "It is given by the inhaled route so the medicine goes straight to where the influenza virus infects the body -- in the breathing passages. By inhaling zanamivir, the drug gets to the site of infection faster than taking it by mouth."

New information from two phase III clinical trials was presented at the meeting*. The findings from the treatment trial, conducted in Australia, New Zealand and South Africa were:Overall, patients taking zanamivir felt:In a second trial conducted in the US, where patients took zanamivir once a day for 28 days to prevent flu, it was found that:

Two thirds of patients who had not been vaccinated against influenza and were given zanamivir were protected from being ill with flu. Those patients who did get ill were less likely to develop illness with fever when receiving zanamivir.

In addition, a phase II treatment trial was presented at the medical conference. Scientists in the Netherlands noted that although the flu virus can become readily resistant to the effects of some other drugs, resistance to zanamivir did not develop in this study. This ensures that the medicine remains effective during treatment.

True influenza (type A and type B) is a serious infection of the breathing passages and is different from the common cold. It can have some serious effects. For example, in the elderly or those who have an existing condition, such as asthma, diabetes or a heart complaint, it can be fatal. Even when those who are otherwise healthy get true flu, it can 'knock us off our feet'.

There are also economic considerations. True flu costs businesses and governments millions every year in lost productivity, days off work and healthcare costs, such as hospital treatment for complications caused by the virus.

Zanamivir is not yet available to the patient or doctor, however, the results of the clinical trials presented at this medical meeting could mean that once it becomes available the future treatment and prevention of influenza will change.

* The results of these clinical trials were presented at ICAAC - the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 September, San Diego, California, USA.

For further information please contact:

Martin Sutton (0171) 493 4060
Nancy Pekarek (0171) 493 4060
Helen Walicka 0802 613 018 (Mobile) or 001 619 224 3621 c/o Holiday Inn San Diego Bayside

CPR Worldwide

Related Influenza Articles from Brightsurf:

Predicting influenza epidemics
Researchers at Linköping University, Sweden, have developed a unique method to predict influenza epidemics by combining several sources of data.

Common cold combats influenza
As the flu season approaches, a strained public health system may have a surprising ally -- the common cold virus.

Scent-sensing cells have a better way to fight influenza
Smell receptors that line the nose get hit by Influenza B just like other cells, but they are able to clear the infection without dying.

New antivirals for influenza and Zika
Leuven researchers have deployed synthetic amyloids to trigger protein misfolding as a strategy to combat the influenza A and Zika virus.

Assessment of deaths from COVID-19, seasonal influenza
Publicly available data were used to analyze the number of deaths from seasonal influenza deaths compared with deaths from COVID-19.

Obesity promotes virulence of influenza
Obesity promotes the virulence of the influenza virus, according to a study conducted in mice published in mBio, an open-access journal of the American Society for Microbiology.

Influenza: combating bacterial superinfection with the help of the microbiota
Frenc researchers and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection.

Chemists unveil the structure of an influenza B protein
MIT chemists have discovered the structure of an influenza B protein called BM2, a finding that could help researchers design drugs that block the protein and help prevent the virus from spreading.

How proteins help influenza A bind and slice its way to cells
Researchers have provided new insight on how two proteins help influenza A virus particles fight their way to human cells.

Eating elderberries can help minimize influenza symptoms
Conducted by Professor Fariba Deghani, Dr. Golnoosh Torabian and Dr.

Read More: Influenza News and Influenza Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to